Article
DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.
Gene therapy - 1 Jan 2008
Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim T E, Cribbs D H, Lobanenkov V V, Agadjanyan M G
Abstract excerpt
The ideal immunological target for cancer vaccine development would meet the criteria of tumor specificity, immunogenicity and vital dependency of the tumor on the functional activities of the antigenic target so as to avoid antigenic loss by mutation. Given that at face value the brother of regulator of imprinted sites (BORIS) transcription factor meets these criteria, we have developed a mutant variant of this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.